Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation on efficacy and safety of capecitabine plus docetaxel versus docetaxel monotherapy in metastatic breast cancer patients pretreated with anthracycline: Randomized phase III study (JO21095)

Next Previous
X
Search
Trial Profile

Evaluation on efficacy and safety of capecitabine plus docetaxel versus docetaxel monotherapy in metastatic breast cancer patients pretreated with anthracycline: Randomized phase III study (JO21095)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Docetaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 17 Jan 2013 New trial record
    • 08 Dec 2012 Analysis of the overall survival data is under examination according to the abstract presented at the 35th Annual San Antonio Breast Cancer Symposium.
    • 08 Dec 2012 Results of an analysis on the effect of circulating tumour cells on response were presented at the 35th Annual San Antonio Breast Cancer Symposium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top